Rivaroxaban vs Edoxaban
## Overview
Rivaroxaban and edoxaban are both factor Xa inhibitors. Edoxaban (Savaysa/Lixiana) is approved for AF and VTE treatment, but it uniquely requires an initial 5–10 days of parenteral anticoagulation before transitioning to oral therapy for VTE.
## Mechanism of Action
Both bind directly to factor Xa active site. Edoxaban's ENGAGE AF-TIMI 48 trial was the pivotal AF trial.
## Pharmacokinetics
Edoxaban: bioavailability ~62%, half-life 10–14 h, once daily, ~50% renal clearance. Rivaroxaban: once daily for AF (with food), ~33% renal clearance. Edoxaban's higher renal clearance makes it more sensitive to renal function changes.
## Pivotal Trial: ENGAGE AF-TIMI 48
Edoxaban 60 mg (or 30 mg for specific patient characteristics) vs. warfarin. Non-inferior for stroke/SE prevention, with significantly fewer major bleeding events including ICH. GI bleeding was similar to rivaroxaban.
## Unique Consideration
The FDA label includes a boxed warning noting that edoxaban has reduced efficacy in patients with CrCl >95 mL/min (high creatinine clearance reduces edoxaban exposure). Rivaroxaban does not have this restriction.
## Key Takeaways
- Edoxaban: once daily, ~50% renal clearance (higher than apixaban/rivaroxaban)
- Rivaroxaban: must be taken with food; no CrCl >95 restriction
- Edoxaban: VTE treatment requires parenteral lead-in
Заключение
Rivaroxaban is preferred when CrCl >95 mL/min (edoxaban loses efficacy). Edoxaban is an alternative for AF and VTE treatment with a good bleeding profile. In practice, apixaban is often preferred over both for its superior efficacy-safety balance.